See more : Becton, Dickinson and Company (BDX) Income Statement Analysis – Financial Results
Complete financial analysis of RedHill Biopharma Ltd. (RDHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RedHill Biopharma Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Silvercorp Metals Inc. (0QZ2.L) Income Statement Analysis – Financial Results
- Erayak Power Solution Group Inc. (RAYA) Income Statement Analysis – Financial Results
- Wison Engineering Services Co. Ltd. (2236.HK) Income Statement Analysis – Financial Results
- Hanyu Group Joint-Stock Co., Ltd. (300403.SZ) Income Statement Analysis – Financial Results
- Public Storage (PSA-PN) Income Statement Analysis – Financial Results
RedHill Biopharma Ltd. (RDHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.redhillbio.com
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 61.80M | 85.76M | 64.36M | 6.29M | 8.36M | 4.01M | 101.00K | 3.00K | 7.01M | 12.00K | 16.00K | 23.00K | 0.00 |
| Cost of Revenue | 3.46M | 33.34M | 49.41M | 36.89M | 2.26M | 2.84M | 2.13M | 30.54M | 22.00M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.05M | 28.46M | 36.35M | 27.47M | 4.03M | 5.52M | 1.88M | -30.44M | -22.00M | 5.96M | 12.00K | 16.00K | 23.00K | 0.00 |
| Gross Profit Ratio | 46.89% | 46.06% | 42.39% | 42.68% | 64.09% | 66.06% | 46.94% | -30,140.59% | -733,300.00% | 85.03% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 3.52M | 7.28M | 29.50M | 16.49M | 17.42M | 24.86M | 32.97M | 25.24M | 17.77M | 12.70M | 8.10M | 6.46M | 5.41M | 736.00K |
| General & Administrative | 28.88M | 54.97M | 76.60M | 25.38M | 11.48M | 7.51M | 8.03M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Selling & Marketing | 2.10M | 9.06M | 11.39M | 49.29M | 18.33M | 12.49M | 12.01M | 1.56M | 1.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.98M | 64.03M | 87.99M | 74.66M | 29.81M | 19.99M | 20.04M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Other Expenses | -44.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 845.00K | 0.00 | 100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -9.56M | 71.31M | 117.49M | 91.15M | 47.23M | 44.85M | 53.85M | 30.64M | 22.01M | 16.61M | 10.78M | 9.06M | 7.90M | 1.73M |
| Cost & Expenses | -6.10M | 104.64M | 166.89M | 128.04M | 49.49M | 47.69M | 55.98M | 30.64M | 22.01M | 17.66M | 10.78M | 9.06M | 7.90M | 1.73M |
| Interest Income | 93.76K | 140.00K | 51.00K | 270.00K | 1.34M | 678.00K | 6.51M | 1.55M | 1.12M | 319.00K | 158.00K | 119.00K | 14.00K | 2.00K |
| Interest Expense | 367.00K | 41.33M | 16.57M | 12.76M | 438.00K | 167.00K | 77.00K | 375.00K | 212.00K | 383.00K | 14.00K | 1.48M | 65.00K | 876.00K |
| Depreciation & Amortization | 1.99M | 8.12M | 18.16M | 8.81M | 1.22M | 89.71K | 81.57K | 44.14K | 36.00K | 27.00K | 24.00K | 24.00K | 15.00K | -63.00K |
| EBITDA | 26.31M | -42.84M | -63.03M | -54.94M | -40.78M | -38.60M | -45.79M | -30.50M | -21.87M | -10.62M | -10.75M | -9.02M | -7.86M | -2.55M |
| EBITDA Ratio | 403.94% | -56.00% | -73.46% | -84.94% | -646.21% | -461.28% | -1,132.67% | -28,664.36% | -694,733.33% | -146.86% | -88,250.00% | -56,837.50% | -36,456.52% | 0.00% |
| Operating Income | 12.63M | -42.84M | -81.14M | -63.68M | -43.20M | -39.33M | -51.97M | -30.54M | -22.00M | -10.65M | -10.77M | -9.04M | -7.87M | -1.73M |
| Operating Income Ratio | 193.95% | -69.33% | -94.61% | -98.95% | -686.71% | -470.47% | -1,297.03% | -30,240.59% | -733,400.00% | -151.80% | -89,766.67% | -56,500.00% | -34,230.43% | 0.00% |
| Total Other Income/Expenses | 11.32M | -28.83M | -16.61M | -12.49M | 897.00K | 511.00K | 6.43M | 1.17M | 812.00K | -64.00K | 144.00K | -1.29M | -7.63M | -811.00K |
| Income Before Tax | 23.95M | -71.67M | -97.74M | -76.17M | -42.30M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Income Before Tax Ratio | 367.75% | -115.97% | -113.98% | -118.36% | -672.45% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| Income Tax Expense | 0.00 | -12.42M | 16.57M | 12.84M | 1.33M | 727.00K | 6.29M | 1.27M | 900.00K | 222.00K | 142.00K | 1.29M | 7.63M | 874.00K |
| Net Income | 23.92M | -59.25M | -114.31M | -89.02M | -43.63M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Net Income Ratio | 367.19% | -95.87% | -133.30% | -138.31% | -693.59% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| EPS | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -94.96 | -76.13 | -49.47 | -68.15 | -80.00 | -128.96 | -19.35 |
| EPS Diluted | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -92.00 | -75.51 | -49.12 | -68.15 | -78.53 | -128.96 | -19.35 |
| Weighted Avg Shares Out | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 309.30K | 277.04K | 216.53K | 155.95K | 129.08K | 120.22K | 131.49K |
| Weighted Avg Shares Out (Dil) | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 319.24K | 279.29K | 218.06K | 155.95K | 131.49K | 120.22K | 131.49K |
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
RedHill Biopharma Announces First Half 2024 Business Highlights
Source: https://incomestatements.info
Category: Stock Reports